If you haven't heard about Gilead's (NASDAQ:GILD) Sovaldi, the hepatitis c cure, you haven't been paying attention. The whole market is aware of the $2.3 billion wonder drug and the fight over its cost.

But Sovaldi isn't Gilead's only wonder drug. There is another -- one which the WHO and CDC recommend people take to help prevent HIV. It's the lynchpin of New York's plan to try and reduce new HIV incidence to the level of tuberculosis by 2020.

Watch the video below to learn more about this incredible opportunity for Gilead investors.